Schizophrenia Research
Volume 118, Issue 1 , Pages 176-182 , May 2010

Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia

  • Bruce J. Kinon

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • Corresponding Author InformationCorresponding authors. Kinon, is to be contacted at Tel.: +1 317 277 7886; fax: +1 317 433 3410, Kollack-Walker, Tel.: +1 317 433 4654; fax: +1 317 276 7100.
    • ,
  • Lei Chen

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • ,
  • Haya Ascher-Svanum

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • ,
  • Virginia L. Stauffer

      Affiliations

    • Lilly, USA, LLC, Indianapolis, IN 46285, USA
    • ,
  • Sara Kollack-Walker

      Affiliations

    • Lilly, USA, LLC, Indianapolis, IN 46285, USA
    • Corresponding Author InformationCorresponding authors. Kinon, is to be contacted at Tel.: +1 317 277 7886; fax: +1 317 433 3410, Kollack-Walker, Tel.: +1 317 433 4654; fax: +1 317 276 7100.
    • ,
  • Wei Zhou

      Affiliations

    • Lilly, USA, LLC, Indianapolis, IN 46285, USA
    • ,
  • Shitij Kapur

      Affiliations

    • Institute of Psychiatry, King's College of London, London, UK
    • ,
  • John M. Kane

      Affiliations

    • Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    • ,
  • Dieter Naber

      Affiliations

    • Hamburg, Germany

Received 18 September 2009 ,Revised 11 December 2009 ,Accepted 14 December 2009.

References 

  1. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur. Psychiatry. 2004;19(1):21–26
  2. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr. Bull. 2008;34(6):1163–1171
  3. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry. 2002;59(5):441–448
  4. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007;33(4):1013–1022
  5. Carpenter WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry. 1988;145(5):578–583
  6. Carpenter WT, Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr. Bull. 1988;14(4):645–652
  7. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33(9):2061–2079
  8. Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr. Res. 2009;113(1):34–40
  9. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am. J. Psychiatry. 2003;160(11):2063–2065
  10. Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, et al. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophr. Res. 2009;107(2–3):275–285
  11. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984;10(3):388–398
  12. Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J. Clin. Psychiatry. 2001;62(suppl 2):22–24
  13. Karow A, Pajonk F-G, Reimer J, Hirdes F, Osterwald C, Naber D, et al. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur. Arch. Psychiatry Clin. Neurosci. 2008;258(3):152–159
  14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13(2):261–276
  15. Kinon BJ, Chen L, Ascher-Avanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 2008;102(1–3):230–240
  16. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35:581–590
  17. Lehman AF. Developing an outcomes-oriented approach for the treatment of schizophrenia. J. Clin. Psychiatry. 1999;60(suppl 19):30–35
  18. Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J. Clin. Psychiatry. 2007;68(3):352–360
  19. Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM. Predicting antipsychotic drug response — replication and extension to six weeks in an international olanzapine study. Schizophr. Res. 2008;101(1-3):312–319
  20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979;134:381–389
  21. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. Int. Clin. Psychopharmacol. 1995;10(Supp.3):133–138
  22. Naber D, Moritz S, Lambert M, Rajonk F, Holzbach R, Mass R, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001;50(1–2):79–88
  23. Nicholson IR, Chapman JE, Neufeld RWJ. Variability in BPRS definitions of positive and negative symptoms. Schizophr. Res. 1995;17(2):177–185
  24. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962;10:799–812
  25. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr. Res. 2007;91(1–3):178–186
  26. Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31(3):703–712
  27. Yamauchi K, Aki H, Tomotake M, Iga J-I, Numata S, Motoki I, et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin. Neurosci. 2008;62(4):404–411

PII: S0920-9964(09)00604-5

doi: 10.1016/j.schres.2009.12.013

Schizophrenia Research
Volume 118, Issue 1 , Pages 176-182 , May 2010

Article Tools

* Image Usage & Resolution